SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)

Introduction: Teprotumumab treatment resulted in statistically and clinically meaningful improvements across multiple facets of active TED and was generally well-tolerated in Phase 2 and 3 trials.(1,2) An initial intravenous infusion of 10 mg/kg followed by 20 mg/kg every 3 weeks was selected based...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Endocr Soc
Auteurs principaux: Xin, Yan, Xu, Fengyan, Gao, Yuying, Bhatt, Nivedita, Chamberlain, Jason, Kovalenko, Maria, Sile, Saba, Sun, Rui, Holt, Robert, Ramanathan, Srini
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Thyroid
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207720/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1047
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires